Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren't Buying It. — WSJ

What happened

Vertex Pharmaceuticals executive chairman Jeff Leiden said the company tested roughly 50 AI companies on data covering 10,000 drug compounds, but none produced a working drug. Drugmaker executives reject claims that AI will soon cure diseases, while saying it can assist researchers with specific tasks.

Confirmed

Global impact / market context

The gap between ambitious claims and reported results suggests AI alone is not yet replacing drug-development work. If its role remains a research aid, drugmakers may gain help selecting targets or patients, but still need scientists and the costly process of testing medicines.

Analyst inference

The article describes drugmakers using AI to help choose targets, refine experimental medicines, and identify suitable patients, while rejecting claims of near-term cures. That points to practical research support, not proven stand-alone drug creation, as the nearer-term commercial use described.

Analyst inference

What to watch

1. Whether Vertex or other drugmakers report AI systems producing working drug candidates, rather than only helping with research tasks, would test the claims described in the article. Analyst inference
2. Drugmakers could continue using AI as a research assistant to select targets, refine experimental medicines, and identify patients who may suit a treatment. Proposed
3. Watch for further statements from drug-company leaders about AI's limits in drug research, particularly whether they describe measurable help beyond the examples given here. Analyst inference

Evidence

• Original source link unavailable